Graft-Versus-Host Disease (GVHD) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies

March 15 11:58 2023
Graft-Versus-Host Disease  (GVHD) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 60+ key pharma and biotech companies are working on 60+ pipeline drugs in the Graft-Versus-Host Disease (GVHD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Graft versus Host Disease (GvHD) market is expected to grow significantly owing to the market penetration of approved therapies and the anticipated label expansion and readily adoption of emerging therapies. Moreover, the growing awareness of cellular therapies, regulatory assistance for research, and innovation are also expected to contribute to the market’s growth.

Major pharma giants such as CSL Behring [CSL 964 Alpha-1 antitrypsin (AAT)], Medac [obnitix (MC0518)], Equillium/Biocon [itolizumab], OncoImmune/Merck (MSD) [MK-7110 (CD24Fc)], ElsaLys Biotech/Mediolanum Farmaceutici Spa [Leukotac (inolimomab)], Xenikos [T-Guard], Mesoblast/Osiris Therapeutics [RYONCIL (remestemcel-L; prochymal)], Syndax Pharmaceutical [axatilimab (SNDX-6532)], Regimmune Corporation (RGI-2001) and several others are actively involved in the development of novel therapies.

Graft-Versus-Host Disease  (GVHD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Graft-Versus-Host Disease Market. 

The Graft-Versus-Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Graft-Versus-Host Disease Pipeline Analysis

Graft-Versus-Host Disease (GVHD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Graft-Versus-Host Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Graft-Versus-Host Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products has been categorized under various ROAs, such as

  • Oral

  • Intravenous

  • Subcutaneous 

Molecule Type

Graft versus host disease Products have been categorized under various Molecule types, such as

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Graft-Versus-Host Disease Therapeutic Segment @

Graft-Versus-Host Disease  (GVHD) Therapeutics Landscape

Several major pharma and biotech companies are actively working in the Graft versus host disease (GVHD) therapeutics market. Currently, ElsaLys Biotech is leading the therapeutics segment, with its drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Graft-Versus-Host Disease (GVHD) Therapeutics Market Include:

AltruBio, Amgen, ASC Therapeutics, AstraZeneca, Biogen, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group, CSL Behring, CTI BioPharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Equillium, GlaxoSmithKline, Glia, Incyte Corporation, Jazz Pharmaceuticals, JCR therapeutics, Kadmon Corporation, MaaT Pharma, Medac, Medsenic, Mesoblas, Millennium Pharmaceuticals/Takeda Oncology, Novartis, OncoImmune/Merck (MSD), Osiris Therapeutics, Pfizer, Plexxikon, Prevention Bio, REGiMMUNE, Regimmune Corporation, Roche-Genentech, SCM Lifescience, Syndax Pharmaceuticals, Synthetic Biologics, Takeda, VectivBio, Xenikos, Xenothera, and others.

Graft-Versus-Host Disease (GVHD) Emerging and Marketed Drugs Covered in the Report Include:

  • AbGn-168H (Neihulizumab): AltruBio

  • Arscimed (arsenic trioxide): Medsenic

  • ASC930: ASC Therapeutics

  • Calquence (Acalabrutinib): AstraZeneca

  • CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring

  • Efavaleukin Alfa (AMG 592): Amgen

  • EQ001 (Itolizumab; Bmab600): Equillium/Biocon

  • Itacitinib: Incyte Corporation

  • Jakafi (Ruxolitinib): Incyte Corporation

  • KD025 (Belumosudil): Kadmon Corporation

  • Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)

  • MaaT013: MaaT Pharma

  • MK-7110 (CD24Fc): OncoImmune/Merck (MSD)

  • Obnitix (MC0518): Medac

  • Pacritinib (Epjevy; ONX-0803): CTI BioPharma

  • RGI-2001: Regimmune Corporation

  • SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical

  • T-Guard: Xenikos

  • Temcell (Ryoncil; Remestemcel-L; Prochymal): JCR therapeutics/ Mesoblast/ Osiris Therapeutics

  • Teplizumab: Prevention Bio

  • Imbruvica (Ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen

  • Jakafi (Ruxolitinib): Incyte Corporation

  • Ornecia (abatacept): Bristol Mayers Squibb

  • Rezurock (Belumosudil): Kadmon Corporation (Subsidiary of Sanofi)

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Graft-Versus-Host Disease Current Treatment Patterns

4. Graft-Versus-Host Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Graft-Versus-Host Disease Late-Stage Products (Phase-III)

7. Graft-Versus-Host Disease Mid-Stage Products (Phase-II)

8. Graft-Versus-Host Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Graft-Versus-Host Disease Discontinued Products

13. Graft-Versus-Host Disease Product Profiles

14. Key Companies in the Graft-Versus-Host Disease Market

15. Key Products in the Graft-Versus-Host Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Graft-Versus-Host Disease Unmet Needs

18. Graft-Versus-Host Disease Future Perspectives

19. Graft-Versus-Host Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States